CND Life Sciences receives FDA breakthrough designation for Syn-One Test

CND Life Sciences has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) for its Syn-One Test®. This designation is intended to expedite the development and review of devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases. The Syn-One Test® is a laboratory-developed test […] The post CND Life Sciences receives FDA breakthrough designation for Syn-One Test appeared first on Longevity.Technology.